- Home
- ASAN vs CELC Comparison
ASAN vs CELC Comparison
Compare ASAN & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASAN | CELC |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.1B |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ASAN | CELC |
|---|---|---|
| Price | $7.26 | $104.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 8 |
| Target Price | $16.17 | ★ $100.13 |
| AVG Volume (30 Days) | ★ 5.3M | 672.2K |
| Earning Date | 03-02-2026 | 02-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.13 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $723,876,000.00 | N/A |
| Revenue This Year | $11.39 | N/A |
| Revenue Next Year | $8.41 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 10.94 | N/A |
| 52 Week Low | $7.15 | $7.58 |
| 52 Week High | $20.74 | $120.32 |
Technical Indicators
Market Signals| Indicator | ASAN | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 24.29 | 48.10 |
| Support Level | $7.30 | $103.20 |
| Resistance Level | $7.78 | $109.75 |
| Average True Range (ATR) | 0.55 | 5.73 |
| MACD | -0.02 | -0.53 |
| Stochastic Oscillator | 11.93 | 47.16 |
Price Performance
Historical ComparisonAbout ASAN Asana Inc.
Asana is a work management platform that allows for increased collaboration and visibility across an organization. Delivered via a SaaS-based model, users can track progress across marketing and development initiatives, create and automate workflows, and manage IT approvals. Revenue is generated on a per-seat basis across several pricing tiers. As of fiscal 2025, the company had over 175,000 customers.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.